Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma

References

• Burns M,
   Google Scholar
  Armstrong SA, Gutierrez A. Chapter 64 - Pathobiology of acute lymphoblastic leukemia. In: Hoffman R, Benz EJ, Silberstein LE, et al., eds. Hematology. 7th ed. Amsterdam, Netherlands: Elsevier; 2018:1005–1019.e1011.
   Google Scholar
• Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003;116:4077.
   PubMed Web of Science ®Google Scholar
• Riolo MT, Cooper ZA, Holloway MP, et al. Histone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in breast cancer. J Biol Chem 2012;287:10885–93.
   PubMed Web of Science ®Google Scholar
• Perri F, Longo F, Giuliano M, et al. Epigenetic control of gene expression: Potential implications for cancer treatment. Crit Rev Oncol/Hematol 2017;111:166–72.
   PubMed Web of Science ®Google Scholar
• Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010;31:27–36.
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014;124:30–9.
   PubMed Web of Science ®Google Scholar
• Schnekenburger M, Florean C, Dicato M, Diederich M. Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments. Curr Top Med Chem 2016;16:745–76.
   PubMed Web of Science ®Google Scholar
• Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007;1:19–25.
   PubMed Web of Science ®Google Scholar
• Biel M, Wascholowski V, Giannis A. Epigenetics–an epicenter of gene regulation: histones and histone-modifying enzymes. Angewandte Chemie 2005;44:3186–216.
   Google Scholar
• Schafer S, Jung M. Chromatin modifications as targets for new anticancer drugs. Arch Pharm. 2005;338:347–57.
   PubMed Web of Science ®Google Scholar
• Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349–52.
   PubMed Web of Science ®Google Scholar
• Lee HY, Fan SJ, Huang FI, et al. 5-Aroylindoles act as selective histone deacetylase 6 inhibitors ameliorating Alzheimer's disease phenotypes. J Med Chem 2018;61:7087–102.
   PubMed Web of Science ®Google Scholar
• Chao SW, Chen LC, Yu CC, et al. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities. Eur J Med Chem 2018;143:792–805.
   PubMed Web of Science ®Google Scholar
• Seidel C, Schnekenburger M, Dicato M, Diederich M. Histone deacetylase 6 in health and disease. Epigenomics 2015;7:103–18.
   PubMed Web of Science ®Google Scholar
• Cosenza M
   Google Scholar
  , Pozzi S. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease. Int J Mol Sci 2018;19:e2337.
   Web of Science ®Google Scholar
• Kumar A, Chauhan S. How much successful are the medicinal chemists in modulation of SIRT1: A critical review. Eur J Med Chem 2016;119:45–69.
   PubMed Web of Science ®Google Scholar
• Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem 2012;4:1439–60.
   PubMed Web of Science ®Google Scholar
• Wickstrom SA, Masoumi KC, Khochbin S, et al. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. The EMBO J 2010;29:131–44.]
   PubMed Web of Science ®Google Scholar
• Chuang C, Pan J, Hawke DH, et al. NudC deacetylation regulates mitotic progression. PLoS One 2013;8:e73841
   PubMed Web of Science ®Google Scholar
• Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Development 2007;21:1790–802.
   PubMed Web of Science ®Google Scholar
• Liu W, Fan LX, Zhou X, et al. HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS One 2012;7:e49418.
   PubMed Web of Science ®Google Scholar
• Pugacheva EN, Jablonski SA, Hartman TR, et al. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell 2007;129:1351–63.
   PubMed Web of Science ®Google Scholar
• Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420–32.
   PubMed Web of Science ®Google Scholar
• Cohen HY, Lavu S, Bitterman KJ, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Molecul Cell 2004;13:627–38.
   PubMed Web of Science ®Google Scholar
• Wang H, Holloway MP, Ma L, et al. Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem 2010;285:36129–37.
   PubMed Web of Science ®Google Scholar
• Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012;4:505–24.
   PubMed Web of Science ®Google Scholar
• Reid T, Valone F, Lipera W, et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 2004;45:381–6.
   PubMed Web of Science ®Google Scholar
• Rivieccio MA, Brochier C, Willis DE, et al. HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci USA 2009;106:19599–604.
   PubMed Web of Science ®Google Scholar
• Best JD, Carey N. Epigenetic therapies for non-oncology indications. Drug Discovery Today 2010;15:1008–14.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kwon S, Yamaguchi T, et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008;28:1688–701.
   PubMed Web of Science ®Google Scholar
• Leonhardt M, Sellmer A, Kramer OH, et al. Design and biological evaluation of tetrahydro-beta-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors. Eur J Med Chem 2018;152:329–57.
   PubMed Web of Science ®Google Scholar
• Ingham OJ, Paranal RM, Smith WB, et al. Development of a Potent and Selective HDAC8 Inhibitor. ACS Med Chem Lett 2016;7:929–32.
   PubMed Web of Science ®Google Scholar
• Wagner FF, Zhang YL, Fass DM, et al. Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers. Chem Sci 2015;6:804–15.
   PubMed Web of Science ®Google Scholar
• Negmeldin AT, Knoff JR, Pflum MKH. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Eur J Med Chem 2018;143:1790–806.
   PubMed Web of Science ®Google Scholar
• Frumm SM, Fan ZP, Ross KN, et al. Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol 2013;20:713–25.
   PubMed Web of Science ®Google Scholar
• Dallavalle S, Pisano C, Zunino F. Development and therapeutic impact of HDAC6-selective inhibitors. Biochem Pharmacol 2012;84:756–65.
   PubMed Web of Science ®Google Scholar
• Nielsen TK, Hildmann C, Dickmanns A, et al. Crystal structure of a bacterial class 2 histone deacetylase homologue. J Mol Biol 2005;354:107–20.
   PubMed Web of Science ®Google Scholar
• Krennhrubec K, Marshall BL, Hedglin M, et al. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 2007;17:2874–8.
   PubMed Web of Science ®Google Scholar
• Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012;119:2579–89.
   PubMed Web of Science ®Google Scholar
• Rey M, Irondelle M, Waharte F, et al. HDAC6 is required for invadopodia activity and invasion by breast tumor cells. Eur J Cell Biol 2011;90:128–35.
   PubMed Web of Science ®Google Scholar
• Nassar M, Samaha H, Ghabriel M, et al. LC3A silencing hinders aggresome vimentin cage clearance in primary choroid plexus carcinoma. Sci Rep 2017;7:8022.
   PubMed Web of Science ®Google Scholar
• Bergman JA, Woan K, Perez-Villarroel P, et al. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem 2012;55:9891–9.
   PubMed Web of Science ®Google Scholar
• Aldana-Masangkay GI, Rodriguez-Gonzalez A, Lin T, et al. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. Leuk Lymp 2011;52:1544–55.
   PubMed Web of Science ®Google Scholar
• Li T, Zhang C, Hassan S, et al. Histone deacetylase 6 in cancer. J Hematol Oncol 2018;11:111
   PubMed Web of Science ®Google Scholar
• Selenica ML, Benner L, Housley SB, et al. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimer's Res Ther 2014;6:12.
   PubMed Web of Science ®Google Scholar
• Parmigiani RB, Xu WS, Venta-Perez G, et al. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci USA 2008;105:9633–8.
   PubMed Web of Science ®Google Scholar
• Kim C, Choi H, Jung ES, et al. HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons. PLoS One 2012;7:e42983.
   PubMed Web of Science ®Google Scholar
• Greer JM, McCombe PA. The role of epigenetic mechanisms and processes in autoimmune disorders. Biol targets Ther 2012;6:307–27.
   PubMedGoogle Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057–61.
   PubMed Web of Science ®Google Scholar
• de Zoeten EF, Wang L, Butler K, et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol 2011;31:2066–78.
   PubMed Web of Science ®Google Scholar
• Miyake Y, Keusch JJ, Wang L, et al. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition. Nature Chem Biol 2016;12:748–54.
   PubMed Web of Science ®Google Scholar
• Li Y, Shin D, Kwon SH. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J 2013;280:775–93.
   PubMed Web of Science ®Google Scholar
• Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol 2011;2011:875824
   PubMed Web of Science ®Google Scholar
• Bobrowska A, Paganetti P, Matthias P, Bates GP. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. PLoS One 2011;6:e20696.
   PubMed Web of Science ®Google Scholar
• Haggarty SJ, Koeller KM, Wong JC, et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003;100:4389–94.
   PubMed Web of Science ®Google Scholar
• Butler KV, Kalin J, Brochier C, et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 2010;132:10842–6.
   PubMed Web of Science ®Google Scholar
• Kalin JH, Bergman JA. Development and therapeutic implications of selective histone deacetylase 6 inhibitors. J Med Chem 2013;56:6297–313.
   PubMed Web of Science ®Google Scholar
• Cosenza M, Civallero M, Marcheselli L, et al. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine. Apoptosis 2017;22:827–40.
   PubMed Web of Science ®Google Scholar
• Vogl DT, Raje N, Jagannath S, et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res 2017;23:3307–15.
   PubMed Web of Science ®Google Scholar
• Yee AJ, Bensinger WI, Supko JG, et al. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncol 2016;17:1569–78.
   PubMed Web of Science ®Google Scholar
• Lee DH, Won HR, Ryu HW, et al. The HDAC6 inhibitor ACY1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells. Int J Oncol 2018;53:844–54.
   PubMed Web of Science ®Google Scholar
• Wang L, Xiang S, Williams KA, et al. Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One 2012;7:e44265.
   PubMed Web of Science ®Google Scholar
• Butler KV, Kozikowski AP. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharmaceut Design 2008;14:505–28.
   PubMed Web of Science ®Google Scholar
• Suzuki T. Explorative study on isoform-selective histone deacetylase inhibitors. Chem Pharm Bull 2009;57:897–906.
   PubMed Web of Science ®Google Scholar
• Marlina S, Shu M-H, AbuBakar S, Zandi K. Development of a Real-Time Cell Analysing (RTCA) method as a fast and accurate screen for the selection of chikungunya virus replication inhibitors. Parasites Vectors 2015;8:579.
   PubMed Web of Science ®Google Scholar
• Freedman JD, Hagel J, Scott EM, et al. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. EMBO Mol Med 2017;9:1067–87.
   PubMed Web of Science ®Google Scholar
• Soto-Pantoja DR, Wilson AS, Clear KY, et al. Unfolded protein response signaling impacts macrophage polarity to modulate breast cancer cell clearance and melanoma immune checkpoint therapy responsiveness. Oncotarget 2017;8:80545–59.
   PubMedGoogle Scholar
• Türker Şener L, Albeniz G, Dinç B, Albeniz I. iCELLigence real-time cell analysis system for examining the cytotoxicity of drugs to cancer cell lines. Exp Ther Med 2017;14:1866–70.
   PubMed Web of Science ®Google Scholar
• Adiguzel E, Yilmaz F, Emirik M, Ozil M. Synthesis and characterization of two new hydroxamic acids derivatives and their metal complexes. An investigation on the keto/enol, E/Z and hydroxamate/hydroximate forms. J Mol Struct 2017;1127:403–12.
   Web of Science ®Google Scholar
• Tsuchiya TN
   Google Scholar
  , Mizuno HS, Matsumoto Y, et al. Benzimidazole derivatives, US Pat. 2005/0267148A1; 2005.
   Google Scholar
• Milik SN, Abdel-Aziz AK, Lasheen DS, et al. Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors. Eur J Med Chem 2018;155:316–36.
   PubMed Web of Science ®Google Scholar
• Sawyer JS, Anderson BD, Beight DW, et al. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem 2003;46:3953–6.
   PubMed Web of Science ®Google Scholar
• Congreve M, Chessari G, Tisi D, Woodhead AJ. Recent developments in fragment-based drug discovery. J Med Chem 2008;51:3661–80.
   PubMed Web of Science ®Google Scholar
• Patrick GL
   Google Scholar
  . An introduction to medicinal chemistry. Oxford, England: Oxford University Press; 2013.
   Google Scholar
• Kawaguchi Y, Kovacs JJ, McLaurin A, et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115:727–38.
   PubMed Web of Science ®Google Scholar
• Hackanson B, Rimmele L, Benkißer M, et al. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. Leukemia Res 2012;36:1055–62.
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Khanim FL, Hayden R, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005;19:1751–9.
   PubMed Web of Science ®Google Scholar
• Lu SH, Wu JW, Liu HL, et al. The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. J Biomed Sci 2011;18:8.
   PubMed Web of Science ®Google Scholar
• Ouyang H, Ali YO, Ravichandran M, et al. Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini. J Biol Chem 2012;287:2317–27.
   PubMed Web of Science ®Google Scholar
• Harris SE, Orpen AG, Bruno IJ, Taylor R. Factors affecting d-block metal-ligand bond lengths: toward an automated library of molecular geometry for metal complexes. J Chem Inform Model 2005;45:1727–48.
   PubMed Web of Science ®Google Scholar
• Mason R,
   Google Scholar
  Randaccio L. The dependence of metal–ligand bond lengths on the nature of ligand groups: centroids of overlap density in metal–ligand bonds. J Chem Soc 1971;1150–4.
   Google Scholar
• Nimmermark A, Öhrström L, Reedijk J. Metal-ligand bond lengths and strengths: are they correlated? A Detailed CSD Analysis. Z Kristallogr Cryst Mater 2013;228:311–17.
   Google Scholar
• Somoza JR, Skene RJ, Katz BA, et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004;12:1325–34.
   PubMed Web of Science ®Google Scholar
• Wang DF, Wiest O, Helquist P, et al. On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J Med Chem 2004;47:3409–17.
   PubMed Web of Science ®Google Scholar